A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Treatment with AZD5991 was associated with high incidence of laboratory troponin elevation and a low overall response rate.
Authors
- Jacqueline Suen Garcia (ORCID: https://orcid.org/0000-0003-2118-6302)
- Manali Kamdar (ORCID: https://orcid.org/0000-0002-1930-152X)
- Ian W. Flinn (ORCID: https://orcid.org/0000-0001-6724-290X)
- Jamal Saeh (ORCID: https://orcid.org/0000-0001-6396-6257)
- Marcio Andrade‐Campos (ORCID: https://orcid.org/0000-0003-1637-7112)
- Susan O’Brien (ORCID: https://orcid.org/0000-0002-2481-7504)
- Margaret Wey
- Javid J. Moslehi (ORCID: https://orcid.org/0000-0001-5443-4312)
- Tapan Mahendra Kadia (ORCID: https://orcid.org/0000-0002-9892-9832)
- Sagar Lonial (ORCID: https://orcid.org/0000-0002-8322-9323)
- Shringi Sharma (ORCID: https://orcid.org/0000-0002-3120-225X)
- Amanda F. Cashen (ORCID: https://orcid.org/0000-0001-6809-4566)
- Mary Liu
- Damilola Olabode (ORCID: https://orcid.org/0000-0001-7675-5707)
- Neha Korde (ORCID: https://orcid.org/0000-0002-5538-4318)
- Pinkal M. Desai (ORCID: https://orcid.org/0000-0002-9816-7284)
- James S. Blachly (ORCID: https://orcid.org/0000-0002-4275-5562)
- Hong Chen (ORCID: https://orcid.org/0000-0002-3762-3565)
- Patricia Cheung
- Firasath Ali Syed
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- Kettering University (US)
- Piedmont Cancer Institute (US)
- Ohio University (US)
- Dana-Farber Cancer Institute (US)
- University of Colorado Cancer Center (US)
- Tennessee Oncology (US)
- UC Irvine Health (US)
- AstraZeneca (United States) (US)
- Community Cancer Center (US)
- The Ohio State University (US)
- University of San Francisco (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-0028
- Citations
- 39
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 17.72
Funders
- Pfizer
- AstraZeneca
- Celgene
- Cytokinetics
- Kiniksa Pharmaceuticals
- BeiGene
- National Institutes of Health
- Genentech
- Daiichi Sankyo Europe